Payment overview · 2025
General Payments
$1,282.93
45 reported records · 20 companies
Healthcare provider profile · identity verified
Cindy S Jacob, MD
Allopathic & Osteopathic Physicians|Family Medicine · KATY, TX · NPI 1174747661
Verified facts
What the public records show
CMS Open Payments records show Cindy S Jacob, MD received $1,282.93 in general payments during 2025 across 45 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Nurtec Odt, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $191.71 | 14.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $190.58 | 14.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $159.99 | 12.5% | 4 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $104.14 | 8.1% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $98.65 | 7.7% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $90.53 | 7.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.14 | 5.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.30 | 5.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.08 | 4.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.52 | 3.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.25 | 2.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.92 | 2.2% | 1 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $22.84 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.07 | 1.7% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $20.15 | 1.6% | 1 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.42 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.15 | 1.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.04 | 1.3% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.88 | 1.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $13.57 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,282.93 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $191.71 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $190.58 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $138.51 | 2 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $104.14 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $98.65 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $70.14 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.08 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.08 | 4 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $58.26 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $46.33 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.46 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.52 | 2 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $33.25 | 2 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.92 | 1 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| REBYOTA Normalized: rebyota |
Biological | Ferring Pharmaceuticals Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $7.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 31 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 237 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 224 | 96 |
| Lisinopril | Lisinopril | 193 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 178 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 66 |
| Gabapentin | Gabapentin | 150 | 73 |
| Losartan Potassium | Losartan Potassium | 128 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 48 |
| Ezetimibe | Ezetimibe | 97 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 32 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 75 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 32 |
| Glipizide | Glipizide | 71 | 29 |
| Omeprazole | Omeprazole | 71 | 31 |
| Furosemide | Furosemide | 70 | 37 |
| Farxiga | Dapagliflozin Propanediol | 69 | 27 |
| Alendronate Sodium | Alendronate Sodium | 67 | 31 |
| Metformin Hcl | Metformin Hcl | 67 | 33 |
| Trazodone Hcl | Trazodone Hcl | 67 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 27 |
| Montelukast Sodium | Montelukast Sodium | 65 | 27 |
| Metformin Hcl Er | Metformin Hcl | 62 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 30 |
| Meloxicam | Meloxicam | 61 | 29 |
| Mounjaro | Tirzepatide | 61 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 28 |
| Tramadol Hcl | Tramadol Hcl | 54 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 27 |
| Ibuprofen | Ibuprofen | 50 | 25 |
| Ozempic | Semaglutide | 50 | 16 |
| Famotidine | Famotidine | 46 | 19 |
| Buspirone Hcl | Buspirone Hcl | 45 | 20 |
| Januvia | Sitagliptin Phosphate | 45 | 17 |
| Prednisone | Prednisone | 44 | 37 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 17 |
| Eliquis | Apixaban | 37 | 16 |
| Trulicity | Dulaglutide | 35 | 11 |
| Simvastatin | Simvastatin | 34 | 17 |
| Bupropion Xl | Bupropion Hcl | 33 | 15 |
| Jardiance | Empagliflozin | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | 16 |
| Sertraline Hcl | Sertraline Hcl | 32 | 15 |
| Clonidine Hcl | Clonidine Hcl | 31 | 14 |
| Linzess | Linaclotide | 31 | 13 |
| Allopurinol | Allopurinol | 30 | 12 |
| Carvedilol | Carvedilol | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 14 |
| Ondansetron Odt | Ondansetron | 30 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | 15 |
| Donepezil Hcl | Donepezil Hcl | 27 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | 12 |
| Rybelsus | Semaglutide | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Constulose | Lactulose | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,282.93 · 45 records | Otsuka America Pharmaceutical, Inc. | ACCRUFER, AIRSUPRA, CONTRAVE, CREON, Cologuard Collection Kit, ENTYVIO, EOHILIA, FARXIGA, Fibroscan, JARDIANCE, Kerendia, LINZESS, NURTEC ODT, OMVOH, OTEZLA, Ozempic, PANCREAZE, REBYOTA, REPATHA, REXULTI, REZDIFFRA, Rybelsus, Sucraid, VOQUEZNA, Wegovy, YUPELRI | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error